Overlapping nongenomic and genomic actions of thyroid hormone and steroids

Steroids

Volumn 76, Issue 9, 2011, Pages 829-833

  Davis, Paul J ^a,b,c   Lin, Hung Yun ^a   Mousa, Shaker A ^b   Luidens, Mary K ^a,c   Hercbergs, Aleck A ^d   Wehling, Martin ^e   Davis, Faith B ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

3,5,3 Triiodo L thyronine; Estrogens; Testosterone; Thyroxine

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ANDROGEN; ANDROSTANOLONE; CELL SURFACE RECEPTOR; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; IODOTHYRONINE; LEVOTHYROXINE; LIOTHYRONINE I 125; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RESVERATROL; STEROID; STILBENE; TESTOSTERONE; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; GENE EXPRESSION; GENOMICS; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART PERFORMANCE; HEART PROTECTION; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; MOLECULAR PATHOLOGY; PHOSPHORYLATION; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR BINDING; REPORTER GENE; REVIEW; THYROID CANCER; TUMOR CELL;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARDIOMEGALY; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; TESTOSTERONE; THYROID GLAND; THYROID HORMONES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959902903     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.012     Document Type: Review

References (68)

1. Cheng SY, Leonard JI, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010;31:139-70.
2. Davis PJ, Davis FB, Mousa SA, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Ann Rev Pharmacol Toxicol 2011;51:99-115.
3. Davis PJ, Shih A, Lin H-Y, Davis FB. Thyroxine promotes association of mitogen-activated protein kinase (MAPK) and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 2000;275:38032-9. (Pubitemid 32004926)
4. Lin H-Y, West BL, Tang H-Y, Passaretti T, Zhang S, Davis FB, et al. Identification of the putative MAP kinase docking site in the thyroid hormone receptor β1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 2003;40:2870-8.
5. Cao HJ, Lin HY, Luidens MK, Davis FB, Davis PJ. Cytoplasm-to-nucleus shuttling of thyroid hormone receptor β1 (TRβ1) is directed from a plasma membrane integrin receptor by thyroid hormone. Endocr Res 2009;34:101-8.
6. Zhu XG, Hanover JA, Hager GL, Cheng SY. Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera. J Biol Chem 1998;273:27058-63. (Pubitemid 28500409)
7. Maruvada P, Baumann CT, Hager GL, Yen PM. Dynamic shuttling and intranuclear mobility of nuclear hormone receptors. J Biol Chem 2003;278:12425-32. (Pubitemid 36800229)
8. Moeller LC, Cao X, Dumitrescu AM, Seo H, Refetoff S. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor β through the phosphatidylinositol 3-kinase pathway. Nucl Recept 2006;4:e020 [Epub 2006 July 7].
9. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004;145:3265-72. (Pubitemid 38829999)
10. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002;21:761-8. (Pubitemid 34146288)
11. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
12. Bergh JJ, Lin H-Y, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of MAPK and induction of angiogenesis. Endocrinology 2005;146:2864-71. (Pubitemid 41002793)
13. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37. (Pubitemid 29019045)
14. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S, et al. Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 2009;101:1725-9.
15. Goodman AD, Hoekstra SJ, Marsh PS. Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7, 12-dimethylbenz(a) anthracene in the rat. Cancer Res 1980;40:2336-42. (Pubitemid 10082247)
16. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007;72:180-7. (Pubitemid 46273502)
17. Lin HY, Sun M, Tang HY, Lin C, Mousa SA, Incerpi S, et al. Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009;296:C980-91.
18. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, et al. Acting via cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006;66:7270-5. (Pubitemid 44197708)
19. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003;23:617-26. (Pubitemid 36358462)
20. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2010. September 15 [Epub ahead of print].
21. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2010. September 28 [Epub ahead of print].
22. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroid correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2010. December 28 [Epub ahead of print].
23. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anticancer agent. Angiogenesis 2008;11:269-76.
24. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Davis FB, et al. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma. Anticancer Res 2009;29:3825-31.
25. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of human medullary carcinoma of the thyroid. J Clin Endocrinol Metab 2010;95:1972-80.
26. Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-α-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 2009;113:182-8.
27. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008;22:2448-55.
28. Hatzoglou A, Kampa M, Kogia C, Charalampopoulos I, Theodoropoulos PA, Anezinis P, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab 2005;90:893-903. (Pubitemid 40279214)
29. Davis PJ, Davis FB, Lin HY. Editorial focus: roles and controls of mTOR in the heart. Am J Physiol Cell Physiol 2010;299:C1250-2.
30. Kuzman JA, O'Connell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 2007;148:3477-84. (Pubitemid 46997021)
31. Kennessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 2006;281:20666-72. (Pubitemid 44115408)
32. Altamirano F, Oyarce C, Silva P, Toyos M, Wilson C, Lavandero S, et al. Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol 2009;202:290-307.
33. Cao X, Kambe F, Moeller LC, Refetoff S, Seo H. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 2005;19:102-12. (Pubitemid 40065962)
34. Kennessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6k pathways. J Biol Chem 2006;281:20666-72. (Pubitemid 44115408)
35. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, et al. The PTEN/Akt pathway dictates the direct αvβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006;66:11331-40. (Pubitemid 46009964)
36. Chen YF, Kobayashi S, Chen J, Redtzke RA, Said S, Liang Q, et al. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 2008;44:180-7.
37. Frantz S, Hu K, Widder J, Weckler B, Scheuermann H, Bauersachs J, et al. Detrimental effects of testosterone on post-myocardial infarction remodeling in female rats. J Physiol Pharmacol 2007;58:717-27.
38. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, Ise T, et al. Androgen receptor counteracts doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 2010;24:1338-48.
39. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009;119:99-106.
40. Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, et al. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg 1996;61:1323-7.
41. Di Fulvio M, Coleoni AH, Pellizas CG, Masini-Repiso AM. Tri-iodothyronine induces proliferation in cultured bovine thyroid cells: evidence for the involvement of epidermal growth factor-associated tyrosine kinase activity. J Endocrinol 2000;166:173-82.
42. Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS, et al. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles effectively inhibit growth of human follicular thyroid carcinoma. Thyroid 2009;20:281-6.
43. Shih A, Lin H-Y, Cao J, Davis FB, Davis PJ. Disparate effects of thyroid hormone on EGF and TGF-α are mediated by cyclic AMP-dependent protein kinase II. Endocrinology 2004;145:1708-17.
44. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors α and β. Int J Oncol 2010;36:1067-80.
45. Kansakar E, Chang YJ, Mehrabi M, Mittai V. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. Am Surg 2009;75:785-9.
46. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164: 658-61.
47. Macheris A, Hauptmann S, Dralle H. Disparities between male and female patients with thyroid cancers: sex different or gender divide? Clin Endocrinol (Oxf) 2006;65:500-5.
48. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004;91:178-85. (Pubitemid 39013062)
49. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008;29: 62-9. (Pubitemid 351201742)
50. Lin HY, Davis PJ, Tang HY, Mousa SA, Luidens MK, Hercbergs AH, et al. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 2009;8: 1877-82.
51. Lin H-Y, Cao HJ, Wu Y-H, Tang H-Y, Grandis JR, Davis PJ, et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008;104:2131-42.
52. Shih A, Lin H-Y, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 2001;40:2870-8. (Pubitemid 32198289)
53. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006;7:423-42. (Pubitemid 43744833)
54. Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 2010. September 28 [Epub ahead of print].
55. Zhao X, Lorenc H, Stephenson H, Wang YJ, Witherspoon D, Katzenellenbogen B, et al. Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells. Proc Natl Acad Sci USA 2005;102:4890-5. (Pubitemid 40471549)
56. Vasudevan N, Davidkova G, Zhu YS, Koibuchi N, Chin WW, Pfaff D. Differential interaction of estrogen receptor and thyroid hormone receptor isoforms on the rat oxytocin receptor promoter leads to differences in transcriptional regulation. Neuroendocrinology 2001;74:309-24. (Pubitemid 33033399)
57. Vasudevan N, Zhu YS, Daniel S, Koibuchi N, Chin WW, Pfaff D. Crosstalk between oestrogen receptors and thyroid hormone receptor isoforms results in differential regulation of the preproenkephalin gene. J Neuroendocrinol 2001;13:779-90. (Pubitemid 32894433)
58. Heimeier RA, Das B, Buchholz DR, Shi YB. The xenoestrogen bisphenol A inhibits postembryonic vertebrate development by antagonizing gene regulation by thyroid hormone. Endocrinology 2009;150:2964-73.
59. Heimeier RA, Shi YB. Amphibian metamorphosis as a model for studying endocrine disruption on vertebrate development: effect of bisphenol A on thyroid hormone action. Gen Comp Endocrinol 2010;168:181-9.
60. Sun H, Shen OX, Wang XP, Zhou L, Zhen SQ, Chen XD. Anti-thyroid hormone activity of bisphenol A, tetrabromobisphenol A and tetrachlorobisphenol A in an improved reporter gene assay. Toxicol in Vitro 2009;23:950-4.
61. Kaneko M, Okada R, Yamamoto K, Nikamura M, Mosconi G, Polzonetti-Magni AM, et al. acts differently from and independently of thyroid hormone in suppressing thyrotropin release from the bullfrog pituitary. Gen Comp Endocrinol 2008;155:574-80. (Pubitemid 351191927)
62. Pratt RD, Johnson JP. Thyroid hormone. Aldosterone antagonism in cultured epithelial cells. Biochim Biophys Acta 1984;805:405-11.
63. Goldman S, Direnfeld M, Abramovici H, Kralem Z. Triiodothyronine (T3) modulates hCG-regulated progesterone secretion, cAMP accumulation and DNA content in cultured human luteinized granulosa cells. Mol Cell Endocrinol 1993;96:125-31.
64. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Progr Horm Res 1997;52:141-64. (Pubitemid 127470209)
65. Lin HY, Tang HY, Lin C, Sun M, Davis FB, Davis PJ. Thyroid hormone induces nuclear accumulation of monomeric integrin αv and formation of integrin-nucleoprotein complexes. Program of the 79th annual meeting of the American Thyroid Association. Thyroid 2007;(Suppl 1):abstract 261.
66. Davis PJ, Tillmann HC, Davis FB, Wehling M. Comparison of the mechanisms of nongenomic actions of thyroid hormone and steroid hormones. J Endocrinol Invest 2002;25:377-88. (Pubitemid 34436135)
67. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009;20:477-82.
68. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008;108:351-61. (Pubitemid 351431076)